Saturday 17 October 2026
Export BIAF’s income statement to Excel — free account
bioAffinity Technologies, Inc.
BIAF Healthcare Diagnostics & Research
In the quarter to June 2026, revenue grew 19.0%, EPS grew 87.5%, free cash flow fell 23.7% and total debt rose 569.7%, each against the same quarter a year earlier.
3.73
0.23
−5.81%
Follow BIAF
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 2 | 2 | 3 |
+8 more TTM periods Free account |
| (1,860.15%) | (622.65%) | (301.83%) | (245.18%) | ||
| (245.51%) | (235.39%) | (170.65%) | (162.88%) | ||
ROIC |
(408.67%) | (613.56%) | (438.42%) | (458.54%) | |
Return on Tangible Assets |
(1,013.64%) | (1,131.70%) | (302.76%) | (224.78%) | |
Average Days of Receivables |
55.35 | 44.19 | 32.10 | 24.18 | |
Free Cash Flow per Share |
(33.16) | (36.46) | (81.79) | (119.65) | |
Free Cash Flow |
(11.56) | (10.93) | (9.39) | (8.51) | |
Capital Expenditures |
(0.09) | (0.02) | (0.06) | (0.06) | |
| Other line items | |||||
Cash ROIC |
(171.18%) | (148.21%) | (65.17%) | (50.78%) | |
Accounts Receivable Turnover |
8.96 | 6.87 | 7.33 | 7.63 | |
Accounts Payable Turnover |
3.61 | 3.42 | 4.83 | 5.67 | |
Inventory Turnover |
61.06 | 64.91 | 104.24 | 161.35 | |
Average Days of Payables |
91.73 | 80.58 | 65.79 | 70.24 | |
Days of Inventory on Hand |
7.79 | 7.51 | 4.62 | 2.63 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
45.14% | 40.06% | 33.90% | 28.60% | |
Selling, General and Administrative Expense of Revenue |
192.29% | 189.10% | 160.88% | 144.56% | |
Share Based Compensation of Revenue |
15.80% | 6.35% | 10.90% | 12.39% | |
Interest Coverage |
(275.76) | (264.59) | (237.58) | (184.08) | |
Operating CF/Net income |
0.76 | 0.69 | 0.63 | 0.57 | |
Depreciation/Fixed assets |
1.32 | 1.88 | 1.90 | 1.76 | |
Capex/Depreciation |
(0.22) | (0.03) | (0.12) | (0.11) | |
Revenue per Share |
16.93 | 18.88 | 53.68 | 95.31 | |
Operating CF per Share |
(32.90) | (36.40) | (81.26) | (118.80) | |
Capex per Share |
(0.26) | (0.05) | (0.53) | (0.85) | |
Capex to Sales |
0.02 | 0.00 | 0.01 | 0.01 |
Columns are period end dates · fundamentals updated 2 Oct 2026